AstraZeneca Pharma India Limited
NSE: ASTRAZENPharmaceuticals
Share price
₹5,719.50
-3.35% close of 8 Oct 2026
Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 7 Oct 2026, the close above is 8 Oct 2026.
Business score
How strong the business is, in one number. The parts behind it are in Pro.
63
out of 100 · worked out 8 Oct 2026
Your ratios
The numbers you want to see first. Tap Edit to change them.
Market cap
₹14,299 Cr
P/E ratio
84.1
P/B ratio
16.4
ROCE
29.3%
ROE
22.9%
Dividend yield
0.6%
Price & valuation chart
How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.
Answers
Simple answers to the questions investors ask most, from the company's own numbers.
How fast it has been growing
Sales grew 31.1% over the past year, and 9.2% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales slipped from 11.2% to 9.6% over the last four years.
Whether it grew faster than its sector
It grew 9.2% a year against a sector median of 13.1% — 3.9 percentage points slower.
Room to re-rate, or risk of de-rating
At 84.1× earnings it costs 3.5× the market, which pays 23.9× across 2199 companies we can price. Its own industry sits at 78.7×, across 5 companies. It is against its own five-year median of 107.7×, the 10th percentile of its own range.
Whether growth justifies the valuation
Priced at 5.6 times its growth rate, on earnings growth of 15%.
| Profit growth | Price per ₹1 profit | Per 1% growth | |
|---|---|---|---|
| AstraZeneca Pharma India Limited — this one | 15%/yr | 84.1× | ₹5.6 |
| Sun Pharmaceutical | 13%/yr | 33.4× | ₹2.6 |
| Divi's Laboratories | 13%/yr | 83.3× | ₹6.4 |
| Torrent Pharmaceuticals | 22%/yr | 78.7× | ₹3.6 |
| Zydus Lifesciences | 32%/yr | 23.1× | ₹0.72 |
| Laurus Labs Limited | 4%/yr | 98.6× | ₹24.7 |
Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
How it compares with its peers
Against companies the exchange files under the same label (Pharmaceuticals), it ranks 14 of 130 on returns, 78 of 127 on growth, 91 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
What makes it hard to beat — and is that still true?
A wide advantage: it earns 29.3% on capital, ahead of 89% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
Whether its growth pays for itself
Yes — Over the last five years it made ₹237 crore of cash from the business, spent ₹26 crore on plant and equipment, and returned ₹235 crore to lenders and shareholders. And the profit is real: of every 100 rupees it reported over 12 years, about 62 arrived as cash. Its cash comes back more slowly than it used to: it went from being paid 34 days before it paid its own suppliers to waiting 50 days for its cash.
Profit reality check
Is the profit real cash? Simple checks on the accounts. Facts only, not advice.
7 of 9 checks clear · 78%
Latest result · Q1 FY27
What the last results showed. Whether management kept its word is in Pro.
Announced 11 Aug 2026 · Standalone · Unaudited
Revenue
₹683 Cr
Revenue vs last year
+29.8%
Revenue vs last quarter
+17.9%
Net profit
₹38 Cr
Profit vs last year
-32.3%
Profit vs last quarter
-15.7%
Net margin
5.6%
EPS
₹15.17
Checklist before you investPRO
Points for and against, in one list.
Key numbers & peers
The main numbers grouped by topic, and how the company compares with similar ones.
Price
- Market cap
- ₹14,299 Cr
- Prev close
- ₹5,719.50
- 52w High
- ₹9,850
- 52w Low
- ₹5,675
- Enterprise value
- ₹14,403 Cr
- Beta
- 0.5
- Price CAGR 1y
- -37.0%
- Price CAGR 3y
- 8.0%
- Price CAGR 5y
- 14.0%
- Price CAGR 10y
- 20.0%
Ratios
- Return on assets
- 9.5%
- PEG ratio
- 5.5
- P/E ratio
- 84.1
- P/B ratio
- 16.4
- EV / EBITDA
- 55.0
- Industry P/E
- 38.0
- ROCE
- 29.3%
- ROCE 5y average
- 28.0%
- ROE
- 22.9%
- Debt / Equity
- 0.1
- Interest coverage
- 64.0
- Dividend yield
- 0.6%
- ROE 3y average
- 23.0%
- ROE last year
- 23.0%
Annual P&L
- Annual revenue
- ₹2,276 Cr
- Annual profit
- ₹188 Cr
- Operating margin
- 12.0%
- Net profit margin
- 8.3%
- EBITDA margin
- 11.5%
- Sales growth 3y
- 31.4%
- Sales growth 5y
- 22.8%
- Profit growth 3y
- 15.0%
- Profit growth 5y
- 16.0%
- EPS
- ₹75.0
- Sales growth TTM
- 31.0%
- Profit growth TTM
- -18.0%
- Dividend payout
- 48.0%
Quarter P&L
- Sales latest quarter
- ₹683 Cr
- Profit latest quarter
- ₹38 Cr
- YoY quarterly sales growth
- 29.7%
- YoY quarterly profit growth
- -32.1%
- OPM latest quarter
- 7.2%
Balance Sheet
- Book Value
- ₹349
- Face Value
- ₹2.0
- Total debt
- ₹111 Cr
- Total cash
- ₹449 Cr
- Borrowings
- ₹111 Cr
- Reserves / Equity
- 173.6
Cash Flow
- Operating cash flow
- -₹15 Cr
- Free cash flow
- -₹18 Cr
- FCF yield
- -0.2%
- Net cash flow
- -₹88 Cr
Shareholding
- Promoter holding
- 75.0%
- FII holding
- 2.7%
- DII holding
- 6.1%
- Public holding
- 16.2%
Peer comparison
| Company | Price ₹ | P/E | Mkt cap ₹ Cr | Div yield % | Profit qtr ₹ Cr | Profit var % | Sales qtr ₹ Cr | Sales var % | ROCE % |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | 1,781.00 | 33.9 | 4,28,057 | 0.90 | 2,901.2 | 6.0 | 15,299.9 | 10.5 | 20.5 |
| Divi's Lab. | 9,588.00 | 85.5 | 2,54,665 | 0.31 | 902.0 | 65.5 | 3,080.0 | 27.8 | 22.0 |
| Torrent Pharma. | 4,716.20 | 80.3 | 1,79,164 | 0.81 | 566.0 | 5.8 | 4,921.0 | 54.9 | 15.2 |
| Zydus Lifesci. | 1,153.00 | 23.6 | 1,14,963 | 0.09 | 990.2 | -35.1 | 8,017.0 | 22.0 | 21.1 |
| Laurus Labs | 2,052.80 | 101.3 | 1,10,699 | 0.10 | 362.1 | 125.5 | 2,026.3 | 29.1 | 17.8 |
| Cipla | 1,327.20 | 29.9 | 1,06,997 | 0.98 | 785.6 | -39.2 | 7,119.3 | 2.3 | 15.5 |
| Mankind Pharma | 2,500.00 | 48.7 | 1,03,876 | 0.04 | 574.1 | 29.6 | 4,030.6 | 12.9 | 13.5 |
| Astrazeneca Phar | 5,918.00 | 85.2 | 14,788 | 0.61 | 37.9 | -32.0 | 682.8 | 29.7 | 29.3 |
| Median | 417.90 | 34.4 | 2,208 | 0.07 | 13.5 | 29.5 | 164.0 | 18.4 | 15.0 |
Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences
Quarterly results
Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.
| Line item | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 295 | 311 | 306 | 383 | 388 | 408 | 440 | 480 | 526 | 559 | 612 | 579 | 683 |
| Expenses | 228 | 258 | 291 | 334 | 349 | 355 | 363 | 394 | 445 | 484 | 567 | 518 | 634 |
| Material Cost | 94 | 9.49 | 0 | 0 | 0 | 0 | |||||||
| Change in Inventories | -123 | -132 | -108 | -331 | 82 | 143 | |||||||
| Purchases of Stock-in-Trade | 288 | 418 | 432 | 697 | 312 | 305 | |||||||
| Employee Cost | 66 | 64 | 60 | 94 | 46 | 79 | |||||||
| Other Expenses | 68 | 85 | 99 | 107 | 78 | 107 | |||||||
| Operating Profit | 67 | 53 | 15 | 49 | 38 | 53 | 77 | 86 | 81 | 75 | 45 | 61 | 49 |
| OPM % | 23 | 17 | 4.92 | 13 | 9.82 | 13 | 17 | 18 | 15 | 13 | 7.33 | 11 | 7.17 |
| Other Income | 8 | 25 | 10 | 9 | -49 | 8 | -26 | 10 | 11 | 1 | 7 | 5 | 9 |
| Exceptional items (within Other Income) | -5.68 | -0.36 | -5.29 | 1.48 | -1.08 | -0.24 | |||||||
| Interest | 0 | 0 | 1 | -0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 |
| Depreciation | 4 | 4 | 4 | 4 | 4 | 9 | 9 | 18 | 17 | 3 | 4 | 6 | 5 |
| Profit before tax | 71 | 73 | 20 | 54 | -15 | 51 | 42 | 78 | 75 | 73 | 47 | 58 | 51 |
| Tax % | 25 | 29 | 23 | 27 | -22 | 25 | 27 | 26 | 25 | 26 | 30 | 23 | 25 |
| Net Profit | 54 | 52 | 16 | 39 | -12 | 38 | 31 | 58 | 56 | 54 | 33 | 45 | 38 |
| EPS in Rs | 22 | 21 | 6.32 | 16 | -4.72 | 15 | 12 | 23 | 22 | 22 | 13 | 18 | 15 |
| Diluted EPS in Rs | 23 | 22 | 22 | 13 | 0 | 0 |
Profit & loss
Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.
| Line item | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 517 | 564 | 544 | 571 | 728 | 832 | 814 | 806 | 1,003 | 1,296 | 1,716 | 2,276 | 2,432 |
| Expenses | 528 | 547 | 506 | 525 | 657 | 711 | 678 | 719 | 838 | 1,111 | 1,462 | 2,014 | 2,202 |
| Material Cost | 287 | 9.49 | |||||||||||
| Change in Inventories | -333 | -488 | |||||||||||
| Purchases of Stock-in-Trade | 1,009 | 1,859 | |||||||||||
| Employee Cost | 257 | 264 | |||||||||||
| Other Expenses | 242 | 369 | |||||||||||
| Operating Profit | -11 | 16 | 37 | 46 | 71 | 121 | 135 | 86 | 165 | 184 | 254 | 262 | 230 |
| OPM % | -2.20 | 2.90 | 7 | 8 | 10 | 15 | 17 | 11 | 16 | 14 | 15 | 12 | 9 |
| Other Income | 6 | 7 | 14 | 12 | 16 | 13 | 13 | 15 | -14 | 51 | -56 | 23 | 21 |
| Exceptional items (within Other Income) | -97 | -5.25 | |||||||||||
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 4.49 | 6 |
| Depreciation | 15 | 17 | 16 | 15 | 15 | 19 | 20 | 17 | 16 | 15 | 40 | 29 | 17 |
| Profit before tax | -21 | 6 | 36 | 44 | 73 | 114 | 127 | 83 | 134 | 220 | 156 | 252 | 228 |
| Tax % | 0 | 9 | 44 | 41 | 25 | 37 | 27 | 26 | 26 | 26 | 26 | 26 | |
| Net Profit | -21 | 5 | 20 | 26 | 54 | 72 | 93 | 62 | 99 | 162 | 116 | 188 | 170 |
| EPS in Rs | -8.34 | 2.10 | 8.02 | 10 | 22 | 29 | 37 | 25 | 40 | 65 | 46 | 75 | 68 |
| Diluted EPS in Rs | 46 | 0 | |||||||||||
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 3 | 5 | 41 | 40 | 37 | 69 | 48 |
Compounded growth
Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.
Compounded sales growth
- 10 years
- 15%
- 5 years
- 23%
- 3 years
- 31%
- TTM
- 31%
Compounded profit growth
- 10 years
- 43%
- 5 years
- 16%
- 3 years
- 15%
- TTM
- -18%
Stock price CAGR
- 10 years
- 20%
- 5 years
- 14%
- 3 years
- 8%
- 1 year
- -37%
Return on equity
- 10 years
- 21%
- 5 years
- 22%
- 3 years
- 23%
- Last year
- 23%
Balance sheet
What the company owns and what it owes, at the end of each year. ₹ crore.
| Line item | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves | 146 | 151 | 218 | 242 | 296 | 359 | 451 | 506 | 584 | 707 | 765 | 868 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 12 | 12 | 9 | 7 | 5 | 36 | 111 |
| Other Liabilities | 261 | 247 | 193 | 214 | 261 | 330 | 306 | 337 | 389 | 362 | 712 | 1,006 |
| Total Liabilities | 412 | 403 | 415 | 461 | 562 | 706 | 775 | 857 | 985 | 1,078 | 1,518 | 1,989 |
| Fixed Assets | 101 | 97 | 87 | 75 | 75 | 72 | 81 | 74 | 69 | 67 | 64 | 117 |
| CWIP | 12 | 6 | 5 | 4 | 7 | 24 | 4 | 2 | 1 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 298 | 299 | 324 | 382 | 480 | 611 | 690 | 780 | 915 | 1,011 | 1,454 | 1,872 |
| Total Assets | 412 | 403 | 415 | 461 | 562 | 706 | 775 | 857 | 985 | 1,078 | 1,518 | 1,989 |
Cash flows
Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.
| Line item | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | -46 | 57 | 38 | 9 | 55 | 87 | 105 | 101 | 58 | 28 | 65 | -15 |
| Cash from Investing Activity | -19 | -4 | 0 | -9 | 4 | -171 | 173 | 5 | 18 | 22 | 31 | 19 |
| Cash from Financing Activity | 0 | -1 | 0 | 0 | 0 | -6 | -9 | -9 | -24 | -44 | -66 | -92 |
| Net Cash Flow | -64 | 53 | 38 | -1 | 59 | -90 | 269 | 96 | 52 | 5 | 31 | -88 |
| Free Cash Flow | -69 | 48 | 33 | 3 | 37 | 74 | 99 | 94 | 53 | 18 | 64 | -18 |
Ratios
How fast customers pay, how long stock sits, and how well capital earns — year by year.
| Line item | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 30 | 54 | 29 | 35 | 40 | 37 | 38 | 39 | 39 | 43 | 39 | 34 |
| Inventory Days | 157 | 141 | 121 | 229 | 186 | 197 | 198 | 164 | 193 | 140 | 208 | 272 |
| Days Payable | 203 | 174 | 184 | 257 | 266 | 251 | 221 | 223 | 231 | 121 | 173 | 207 |
| Cash Conversion Cycle | -16 | 21 | -34 | 7 | -39 | -17 | 15 | -20 | 1 | 62 | 74 | 99 |
| Working Capital Days | -15 | -28 | -36 | -8 | -14 | -16 | -17 | -34 | -18 | 20 | 22 | 50 |
| ROCE % | -13 | 4 | 15 | 19 | 27 | 34 | 30 | 16 | 31 | 31 | 33 | 29 |
Price trend
The price as a Renko brick chart: small moves drop out so the bigger path stands out.
Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.
Open interestPRO
Where option traders are positioned on this stock.
Industry numbers
The numbers that matter most in this industry, from the company's own filings.
1 when an audit qualification is filed as repetitive
0.00flag
2026-03-31
the company's own unlisted debt securities in default at period end
0.00cr
2026-06-30
the company's own loans / revolving facilities in default at period end (standalone filing)
0.00cr
2026-06-30
guarantees / comfort given for promoter, promoter group, directors and KMP
0.00cr
2026-03-31
loans outstanding to promoter, promoter group, directors and KMP (governance filing)
0.00cr
2026-03-31
security given for the borrowing of promoter, promoter group, directors and KMP
0.00cr
2026-03-31
FY revenue / permanent employees + workers, same basis (calc)
2,99,47,368inr
2026-03-31
News
News and filings about AstraZeneca Pharma India Limited. Open one to see why it matters.
18 Sept, 18:05 IST · Company event · low impact
AstraZeneca Pharma India Limited: Action(s) taken or orders passed
Supply chain
Who it buys from, sells to and competes with — as recorded in our map of company links.
Competes with
Uses as raw material
- Active pharmaceutical ingredients (APIs) and excipients
- Packaging materials
Buys drug ingredients from
- AstraZeneca AB, Sweden
- AstraZeneca UK Limited
Sells to
- AstraZeneca AB, Sweden · Clinical trial and marketing support services to parent group
- Mankind Pharma Limited · Symbicort (budesonide/formoterol fumarate) — 5-yr exclusive India distribution & promotion…
- Sun Pharmaceutical · Sodium Zirconium Cyclosilicate (SZC) for hyperkalaemia — Sun Pharma promotes/distributes a…
About
What the company is, from our own records: where it sits, where it makes things, and what it is made of.
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Classification
- Healthcare › Pharmaceuticals
- ISIN
- INE203A01020
News impact
Big market events that reach AstraZeneca Pharma India Limited, and how the effect spreads.
30 Sept, 20:12 IST · Market event · medium impact
Kerala HC judgment gives Centre another route to tackle high-priced patented medicines
Court lets government get patented drugs made cheaply for public health, hurting costly patent sellers but helping generic and ingredient makers.
Who it hits first
- A court says the central government can ask another company to make costly patented medicines for public health schemes, if legal steps are met.
- Makers of high-priced patented drugs, like AstraZeneca India and Sun Pharma's specialty arm, face cheaper government-backed copies.
- Generic drug and ingredient makers, like Cipla, Divi's Labs and Laurus Labs, could win new government supply orders.
- Hospitals and pharmacies see little instant change; the fight is over who makes the pills.
Who may gain
- Cipla (generic drug maker) — could be picked to make low-cost versions for government programmes.
- Divi's Laboratories (drug-ingredient maker) — more generic volumes mean more ingredient orders.
- Laurus Labs (contract drug maker) — similar ingredient and manufacturing upside.
- Patients in public-health schemes — cheaper access if the route is used.
Along the supply chain
Downstream
Downstream are government hospitals, clinics and distributors in public-health schemes, which get cheaper patented drugs, while patent sellers lose sales.
Upstream
Upstream are ingredient and raw-material suppliers like Divi's Labs and Laurus Labs, which gain if generic copies need more active ingredients.
Where demand moves
Business
Government health programmes may shift orders from costly patent sellers to approved generic makers; overall pill volumes stay similar, but who gets paid changes.
Capital
Investors turn cautious on patent-heavy sellers and look toward generic and ingredient makers that could win state orders.
How it spreads across sectors
Healthcare
Patent-holding sellers face price cuts while approved generic and ingredient makers gain order chances; hospitals see little direct change.
When it plays out
Immediate
In 1–7 days drug stocks wobble as investors reprice patent risk and generic hopes.
Medium term
In 1–6 months any first government authorisation to a generic maker sets prices and volumes.
Short term
In 1–4 weeks lawyers parse the judgment and government hints which drugs or schemes come first.
28 Jun, 02:05 IST · Market event · medium impact
AbbVie (ABBV) to Acquire Apogee Therapeutics
Who it hits first
- AbbVie (ABBV) and Apogee Therapeutics are US-listed; neither is in the Indian knowledge graph — zero direct impact on Indian listed companies.
Who may gain
- Sentiment-level read-across to Indian biologics/biosimilar innovators (immunology-biologics theme stays in focus) and, as a diffuse long-term theme, the CDMO/CRO category as global pharma deploys M&A capital.
Along the supply chain
Downstream
No downstream supply-chain link — a US biotech acquisition does not change product flows to or from any Indian listed company.
Upstream
No upstream supply-chain link — AbbVie and Apogee are US entities; no Indian listed company supplies APIs, intermediates or services into this specific transaction.
Where demand moves
Business
No direct business-demand flow — the AbbVie-Apogee deal neither creates nor destroys orders for any Indian company. Any effect (global pharma capital deployment lifting long-term outsourcing demand for Indian CDMO/CRO players) is a diffuse second-order theme, not a measurable order shift.
Capital
Capital-flow read-across only — a global immunology M&A reinforces a positive innovator-pharma narrative that can support Indian pharma valuations at the margin; the effect is sentiment-level and strongest for biologics/biosimilar names such as Biocon.
How it spreads across sectors
Healthcare
negligible — hospital operators have no business channel to a US drug-developer acquisition
Pharma
mild positive sentiment from the global pharma M&A consolidation/innovation theme
Dividends, splits & big trades
Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.
Dividends
| 31 Jul 2026 | unspecified | ₹36 |
|---|---|---|
| 18 Jul 2025 | unspecified | ₹32 |
| 5 Jul 2024 | unspecified | ₹24 |
| 14 Jul 2023 | unspecified | ₹16 |
| 7 Jul 2022 | unspecified | ₹8 |
| 18 Aug 2021 | interim | ₹2 |
| 20 Aug 2020 | interim | ₹2 |
| 20 Aug 2019 | interim | ₹1 |
Splits, bonuses & buybacks
- daily-prices repair: 8 rows from NSE's archive (replace 1, delete 0, insert 7), 2016-10-30..2026-02-01 (docs/flat_day_repair.md)1× · 30 Oct 2016
Documents
Annual reports, results presentations and earnings calls, straight from the source.
- Annual report · 2025-2618 Jul 2026
Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.